正面交锋分析：Innate Pharma（纳斯达克股票代码：IPHA）对比 Sangamo Therapeutics（纳斯达克股票代码：SGMO）

Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) and Innate Pharma (NASDAQ:IPHA – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sangamo Therapeutics and Innate Pharma, as reported by MarketBeat.

Sangamo Therapeutics currently has a consensus target price of $12.80, suggesting a potential upside of 680.49%. Innate Pharma has a consensus target price of $9.12, suggesting a potential upside of 179.33%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Innate Pharma.

Volatility & Risk

Sangamo Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

Earnings & Valuation

This table compares Sangamo Therapeutics and Innate Pharma's top-line revenue, earnings per share and valuation.

Innate Pharma has lower revenue, but higher earnings than Sangamo Therapeutics.

Profitability

This table compares Sangamo Therapeutics and Innate Pharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

59.3% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 10.2% of Innate Pharma shares are held by institutional investors. 2.6% of Sangamo Therapeutics shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

About Sangamo Therapeutics

(Get Rating)

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

About Innate Pharma

(Get Rating)

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.